

EXPRESSION OF INTEREST FORM

AMETHYST: A multicentre, double-blind, placebo-controlled randomised trial comparing a combination of methotrexate (MTX) and mifepristone versus methotrexate alone as a medical treatment for tubal ectopic pregnancy (tEP)

Funder: NIHR Sponsor: University of Aberdeen/NHS Grampian

Please return your completed Expression of Interest to the AMETHYST Trial Manager Claire Cochran at amethyst@abdn.ac.uk

1. Site informa	tion
Site name	
Department	
2. Contact deta	ails for Principal Investigator (PI) at site
Name	
Email	
Telephone	
(please attach CV	and current GCP if available)
3. Contact deta	ails for lead Research Nurse (RN) at site (if known)
Name	
Email	
Telephone	
(please attach CV	and current GCP if available)
4. Contact deta	ails for co-investigators at site (if known)
Name	
Email	
Telephone	

(please attach CV and current GCP if available)

5. Associate PI scheme				
Are you interested in being involved in t NIHR Associate Principal Investigator S	Scheme?			
(www.nihr.ac.uk/health-and-care-professionals/c	career-			
development/associate-principal-investigator-sch	neme.num)			
6. R&D contact (if known)				
7. Pl's previous involvement in resear	rch			
Current or recent (within 5 years) involvement in research	Drug study: Current ☐ Recent ☐ Other study: Current ☐ Recent ☐			
Date of last GCP training				
If you have previously been involved	d in research:			
What was the site recruitment target in terms of the overall recruitment target?				
Was it met?	Yes □ No □			
If not, any explanation of why not.				
If you have not previously been involuded Has your ■ lead RN □ (and/or) ■ co-investigator(s) □ had current (within 5 years) involvement study:				
Other study:	Current □ Recent □			
Please provide any other information relevant to research experience				
8. Participant enrolment				
Can you estimate how many eligible participants your site could recruit to AMETHYST per month?				
Total number of ectopic pregnancies / to ectopic pregnancies per year	tubal			

Number of tubal ectopic Pregnancies treated with MTX	
Are you aware of any other research studies ongoing at your site or likely to be conducted whilst AMETHYST is ongoing that may have a conflicting interest with this study? Please give details	
What challenges, if any, do you foresee with recruitment and/or retention within AMETHYST at your site?	
Sites will be opened to recruitment in a phased manner over 9 months from approx. August 2025. Any preferences for when your site would open to recruitment?	2025 (Q3/4) □ 2026 (Q1/2) □
9. Staff, facilities and resources	
Are there staff available (e.g. research nurse) to support recruitment and retention in AMETHYST?	
Do you routinely take progesterone serum levels in the diagnostic process for ectopic pregnancy?	
Would your laboratory support progesterone levels being taken at the same time as all hCG blood tests as per routine methotrexate follow up?	
Do you have access to other resources to support AMETHYST (e.g. clinical space/computers/space for recruitment)?	
10. After English, what would you say are tl at your site?	he top 3 other languages spoken by patients

I. How do you manage locally with translation of medical information for non-English beakers/readers? Do you use Language Line?

Thank you for completing this expression of interest.

Please return the completed form to amethyst@abdn.ac.uk

We look forward to working with you.